The Cancer Pill Not Taken Costs Insurers in Long Run
As oral chemotherapy becomes more common, so does nonadherence. Cost is only one of the reasons.
Frank Diamond
The push to integrate health care services and financing may portend a move away from behavioral health carve-outs
Michael D. Dalzell
Research says PA can help make treatments safer and more cost-effective, but data sharing must improve
Thomas Reinke
Even today, studies show, only half of treatments are truly based on evidence. Here’s an organization looking to better that share, and it may behoove health plans to help.
Joseph Burns
When a respected provider organization took a stand against the costly new cancer drug, it was both surprising and encouraging
Michael D. Dalzell
Departments
While local governments ponder just what course to take, health plans prepare to grab as much market share as possible
Case management, prior authorization, and drug utilization control are required
A summary of ECRI Institute’s Emerging Technology Evidence Report
Devices that selectively destroy the renal nerves that affect hypertension have gained international approval, and availability in the United States is not far off
The insurer’s tracking effort helps physicians keep tabs on patients who may not be taking their drugs correctly
News & Commentary
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.